- Home
- HYMC vs KNSA Comparison
HYMC vs KNSA Comparison
Compare HYMC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$21.45
HOLD
Current Price
$59.11
Company Overview
Basic Information| Metric | HYMC | KNSA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United Kingdom |
| Employees | 51 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HYMC | KNSA |
|---|---|---|
| Price | $21.45 | $59.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $60.86 |
| AVG Volume (30 Days) | ★ 2.1M | 522.3K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ N/A | $220.33 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $3.02 | $26.27 |
| 52 Week High | $58.73 | $59.94 |
Technical Indicators
Market Signals| Indicator | HYMC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 70.96 |
| Support Level | $6.49 | $40.67 |
| Resistance Level | $29.65 | $59.87 |
| Average True Range (ATR) | 2.11 | 2.03 |
| MACD | -0.21 | 1.07 |
| Stochastic Oscillator | 4.77 | 84.72 |
Price Performance
Historical Comparison HYMC
KNSA
About HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.